Search

Displaying results 2871 - 2880 of 10000 in total
  1. Drug

    Diethylstilbestrol

    go.drugbank.com/drugs/DB00255
    ApprovedWithdrawn

    A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. … (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]

    Categories: Hormonal Contraceptives for Systemic Use, Estrogens, Non-Steroidal
  2. Drug

    Ceftobiprole

    go.drugbank.com/drugs/DB04918
    ApprovedWithdrawn

    for skin and skin structure infections and bacteremia in April 2024. … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European

  3. Drug

    Canrenoic acid

    go.drugbank.com/drugs/DB09015
    ApprovedInvestigationalWithdrawn

    Canrenoic acid (as the salt potassium canrenoate) is an aldosterone antagonist. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.

  4. Drug

    Sipavibart

    go.drugbank.com/drugs/DB21908
    ApprovedInvestigational

    [A274088] Sipavibart is approved for the pre-exposure prophylaxis treatment of COVID-19 in immunocompromised patients.[L53418] … [L53418] Sipavibart gained its first global approval in Japan in December 2024.[A274088] It was later approved in Europe in January 2025 and in Canada in March 2025.

    Categories: Antiinfectives for Systemic Use
  5. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. … It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.

    Categories: Tests for Bile Duct Patency
  6. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.

  7. Drug

    Manidipine

    go.drugbank.com/drugs/DB09238
    ApprovedInvestigationalWithdrawn

    It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages. … Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive.

  8. Target

    Antigen peptide transporter 1

    go.drugbank.com/bio_entities/BE0003109
    TransporterHumans

    In complex with TAP2 mediates unidirectional translocation of peptide antigens from cytosol to endoplasmic reticulum (ER) for loading onto MHC class I (MHCI) molecules (PubMed:25377891, PubMed:25656091 … Subsequently ATP hydrolysis resets the transporter to the 'inward facing' state for a new cycle (PubMed:11274390, PubMed:25377891, PubMed:25656091).

    Synonyms: Peptide transporter involved in antigen processing 1
  9. Drug

    Cladribine

    go.drugbank.com/drugs/DB00242
    ApprovedInvestigational

    [A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell … [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718]

  10. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. … Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.